➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Merck
McKinsey
Harvard Business School
Moodys

Last Updated: July 13, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 210331


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 210331 describes YUTIQ, which is a drug marketed by Eyepoint Pharms and is included in one NDA. There are six patents protecting this drug. Additional details are available on the YUTIQ profile page.

The generic ingredient in YUTIQ is fluocinolone acetonide. There are twelve drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the fluocinolone acetonide profile page.
Summary for 210331
Tradename:YUTIQ
Applicant:Eyepoint Pharms
Ingredient:fluocinolone acetonide
Patents:6
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 210331

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:IMPLANT;INTRAVITREALStrength0.18MG
Approval Date:Oct 12, 2018TE:RLD:Yes
Regulatory Exclusivity Expiration:Nov 12, 2021
Regulatory Exclusivity Use:NEW PRODUCT
Patent:  Start TrialPatent Expiration:Apr 26, 2020Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
Patent:  Start TrialPatent Expiration:Apr 26, 2020Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 210331

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eyepoint Pharms YUTIQ fluocinolone acetonide IMPLANT;INTRAVITREAL 210331-001 Oct 12, 2018   Start Trial   Start Trial
Eyepoint Pharms YUTIQ fluocinolone acetonide IMPLANT;INTRAVITREAL 210331-001 Oct 12, 2018   Start Trial   Start Trial
Eyepoint Pharms YUTIQ fluocinolone acetonide IMPLANT;INTRAVITREAL 210331-001 Oct 12, 2018   Start Trial   Start Trial
Eyepoint Pharms YUTIQ fluocinolone acetonide IMPLANT;INTRAVITREAL 210331-001 Oct 12, 2018   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
AstraZeneca
Express Scripts
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.